Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma

BACKGROUND: While cancer immunotherapies including checkpoint blockade antibodies, adoptive T cell therapy, and even some vaccines have given rise to major clinical responses with durability in many cases, a subset of patients who initially respond subsequently develop secondary resistance to therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Trujillo, Jonathan A., Luke, Jason J., Zha, Yuanyuan, Segal, Jeremy P., Ritterhouse, Lauren L., Spranger, Stefani, Matijevich, Karen, Gajewski, Thomas F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839232/
https://www.ncbi.nlm.nih.gov/pubmed/31703593
http://dx.doi.org/10.1186/s40425-019-0780-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839232/
https://www.ncbi.nlm.nih.gov/pubmed/31703593
http://dx.doi.org/10.1186/s40425-019-0780-0

Ejemplares similares